While most of the attention in the biotech sector is focused on potential COVID-19 treatments or vaccines, the author of today’s article argues that there’s “a better way to play the sector, which is via companies whose roles in the daily grind of drug manufacturing and research will remain crucial regardless of the ups and downs of any particular acute developments.” He proceeds to highlight a little-known biotech that, while likely to play a role in the manufacturing of any successful COVID-19 related treatments, does not have its fortunes tied to the success of any particular candidate – and thus is positioned to continue its upward trajectory. For more, CLICK HERE.
